Omentin-1 vs Oxyntomodulin
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Oxyntomodulin (Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Oxyntomodulin |
|---|---|---|
| Category | Diabetes & Metabolic | Weight Management |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide |
| Molecular Weight | ~35 kDa | ~4,200 Da |
| Half-Life | hours | 12-15 minutes |
| Amino Acids | 313 | 37 |
| Typical Dose | No approved human dose; research use only | Research doses vary; commonly 100-300 mcg in small human studies |
| Route | IV|SC | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 80 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Oxyntomodulin Benefits
- ✓reduces appetite
- ✓increases satiety
- ✓supports weight loss
- ✓improves postprandial metabolic signaling
Omentin-1 Dosing
not established|not established
Oxyntomodulin Dosing
Research-only dosing|Subcutaneous or IV administration in trials|Pair with calorie restriction and monitoring
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Oxyntomodulin Side Effects
- ⚠nausea
- ⚠GI discomfort
- ⚠decreased appetite beyond target
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Oxyntomodulin
Human studies showed acute reductions in food intake and modest weight loss, helping establish the GLP-1 and glucagon co-agonism concept. It remains a foundational peptide for obesity and satiety research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.